DBV TECHNOLOGIE/S (NASDAQ:DBVT) Stock Rating Lowered by ValuEngine

ValuEngine cut shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a hold rating to a sell rating in a research report sent to investors on Saturday morning, ValuEngine reports.

Several other equities research analysts have also recently weighed in on DBVT. Zacks Investment Research upgraded DBV TECHNOLOGIE/S from a sell rating to a hold rating in a research note on Monday, January 13th. BidaskClub upgraded DBV TECHNOLOGIE/S from a buy rating to a strong-buy rating in a research note on Friday, January 3rd. Stifel Nicolaus upgraded DBV TECHNOLOGIE/S from a hold rating to a buy rating and upped their target price for the stock from $10.00 to $18.00 in a research note on Wednesday, January 8th. HC Wainwright restated a buy rating and set a $25.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Thursday, December 19th. Finally, Citigroup initiated coverage on DBV TECHNOLOGIE/S in a research note on Monday, December 16th. They set a buy rating and a $14.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. DBV TECHNOLOGIE/S has an average rating of Buy and a consensus price target of $17.00.

NASDAQ DBVT opened at $12.45 on Friday. The business has a fifty day moving average price of $10.41 and a two-hundred day moving average price of $9.14. The company has a debt-to-equity ratio of 0.19, a current ratio of 3.00 and a quick ratio of 2.96. DBV TECHNOLOGIE/S has a fifty-two week low of $5.77 and a fifty-two week high of $13.49. The stock has a market capitalization of $1.18 billion, a PE ratio of -3.67 and a beta of 1.91.

Several institutional investors and hedge funds have recently made changes to their positions in DBVT. Cubist Systematic Strategies LLC lifted its stake in shares of DBV TECHNOLOGIE/S by 10.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 13,284 shares of the company’s stock valued at $109,000 after acquiring an additional 1,229 shares during the last quarter. LeJeune Puetz Investment Counsel LLC lifted its stake in shares of DBV TECHNOLOGIE/S by 11.4% in the 3rd quarter. LeJeune Puetz Investment Counsel LLC now owns 14,650 shares of the company’s stock valued at $126,000 after acquiring an additional 1,500 shares during the last quarter. Jane Street Group LLC bought a new position in shares of DBV TECHNOLOGIE/S in the 2nd quarter valued at $213,000. Bluefin Trading LLC bought a new position in shares of DBV TECHNOLOGIE/S in the 3rd quarter valued at $215,000. Finally, Parametric Portfolio Associates LLC lifted its stake in shares of DBV TECHNOLOGIE/S by 27.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 66,958 shares of the company’s stock valued at $550,000 after acquiring an additional 14,454 shares during the last quarter. Institutional investors own 33.38% of the company’s stock.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Featured Article: Outstanding Shares, Buying and Selling Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.